Induction of liver NQO1 activity in juvenile female rats treated for 3 d (10 mg/kg qd SERMs or 0.1 mg/kg qd E2 or vehicle control). Induction of liver.

Slides:

Advertisements

Similar presentations

miR-133a positively regulated p53/p21 pathway.

Advertisements

Body weight at harvest (g) Left kidney:body weight ratio (g/kg)

T3 increased J7-TRα1 cell migration and proliferation both in vitro and in vivo. T3 increased J7-TRα1 cell migration and proliferation both in vitro and.

Pioglitazone treatment prevents TRPC6 overexpression and podocyte injury in the adriamycin (ADRIA)–induced nephropathy rat model for FSGS. ADRIA-induced.

Effects of senescent cells on activity.

25(OH)D and 1,25(OH)2D perfusion treatment effect on cancer-related markers: IF stains illustrating expression levels for Ki-67 (A), cyclin D1 (B), ErbB-2.

Oxalate handling for N. albigula in vivo for animals that completed the diet trial (n = 7). Oxalate handling for N. albigula in vivo for animals that completed.

Fig. 1 MT-2 ameliorates asthmatic pulmonary resistance.

Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. Treatment with BLU9931 leads to tumor regression in.

Numerous protumorigenic proteins are largely unaltered by obesity.

Fig. 4. Expression of HGF in liver ECs cooperates with NOX4 inhibition to enhance engraftment of regenerative hepatocytes. Expression of HGF in liver ECs.

Improvement of insulin sensitivity by treatment of the annexin A1 receptor agonist in HFD mice. Improvement of insulin sensitivity by treatment of the.

PERK activator decreases pathological tau species in vitro

Effect of expression of constitutively active CAMKK2 on AMPK activation and the cell cycle in G361 cells. Effect of expression of constitutively active.

Tissue‐specific differences in the levels of CoQ9, CoQ10, and DMQ9, and in the DMQ9/CoQ9 ratio after β‐RA treatment in Coq9R239X mice Tissue‐specific differences.

Mechanism of piperlongumine induced Sp downregulation.

Reversal of MOR lysosomal targeting by silencing enhanced Rab7 expression. Reversal of MOR lysosomal targeting by silencing enhanced Rab7 expression. A:

Effect of insulin on hepcidin expression in HepG2 cells.

ONC201 activates the ISR. ONC201 activates the ISR. (A) Western blotting analysis for ATF4, CHOP, ATF3, and TRB3 on lysates from HCT116 cells cultured.

AAS-dependent induction of autophagic flux in ARPE-19.

Peli1 levels are reduced in bid−/− microglia upon LPS stimulation.

Phosphorylated CREB levels were assessed in the hippocampus at 20 min after cue and contextual fear conditioning. Phosphorylated CREB levels were assessed.

CPI-444 efficacy requires CD8+ T cells and is associated with increased CD73 expression. CPI-444 efficacy requires CD8+ T cells and is associated with.

Fig. 3 Biological function of TG2 and the interaction with MT-2.

GA blocks HIF activity and reduces HIF target expression.

Gramicidin A (GA) decreases HIF protein expression in RCC cells.

Variation in dUTPase expression in cell lines.

Identification of NSC as a FADD-kinase inhibitor.

Activation of CHOP and DR5 by DIM-C-pPhtBu.

Tlr4−/− attenuates symptomatic parameters of gut toxicity: diarrhea and weight loss. Tlr4−/− attenuates symptomatic parameters of gut toxicity: diarrhea.

Cytokine expression in the ileum and colon.

CAT displays very high in vivo stability as exemplified by a rat PK study. CAT displays very high in vivo stability as exemplified by a rat.

Depletion of HDAC2 sensitizes cells to epirubicin-induced apoptosis.

Effect of G9a on the expression of GSH synthesis enzymes.

A, one-step viral growth curves: RT treatment increased the virus yield in MV-CEA–treated U87 cells by up to 2 log as compared with MV-CEA infection only.

Curcumin suppresses the expression of antiapoptotic proteins in multiple myeloma cells. Curcumin suppresses the expression of antiapoptotic proteins in.

Effect of SFN on the protein expression of Nrf2, HO-1, and NQO1 in JB6-shMock and JB6-shNrf2 cells. Effect of SFN on the protein expression of Nrf2, HO-1,

Angiogenesis in tumors formed by cells varying in the expression of CXCR2. Angiogenesis in tumors formed by cells varying in the expression of CXCR2. A,

Biological effects of BRAF silencing: growth curves of A375 (A) and ARO (B) cell lines in the absence or presence of doxycycline. Biological effects of.

HDACI treatment leads to down-regulation of AR and neuroendocrine transdifferentiation of LNCaP or LAPC4 cells. HDACI treatment leads to down-regulation.

Src expression in a panel of human TCC cell lines.

Expression pattern of TLR-4 and MyD88 in EOC cells.

Pharmacodynamic evaluation of VT-464 and ABI in MR49F xenograft model.

Staurosporine induces changes in MMP

COX-2, Oct-4, and ALDH-1 expression in the mammary gland.

Micro-PET/CT images of 64Cu-Sar-chTNT-3 in MAD109-bearing BALB/c mice following VP-16 pretreatment. Micro-PET/CT images of 64Cu-Sar-chTNT-3 in MAD109-bearing.

DNA demethylation reactivates GSN expression in gastric cancer cells.

Neutralization of CSF1 and Ad5-HRG treatment.

Three-day biodistribution of 125I-labeled chTNT-3 administered at (A) 1, 2, or 3 days after pretreatment with VP-16 (30 mg/kg) in MAD109 bearing BALB/c.

Ki-67 expression in M31- and H3-treated tumors (A) and respective Ki-67 labeling indices in the two groups of tumors (B). Ki-67 expression in M31- and.

SBC-5 miR-335+, but not SBC-5 miR-29a+, exhibited reduced IGF-IR expression. SBC-5 miR-335+, but not SBC-5 miR-29a+, exhibited reduced IGF-IR expression.

CRA inhibits the growth of human tumor xenografts in vivo.

Changes in signal transduction pathway induced by gefitinib.

NT157 treatment inhibits LNCaP xenograft growth and delays castration-resistant progression. NT157 treatment inhibits LNCaP xenograft growth and delays.

Immunohistochemical staining for FOXO3a of breast cancer tumor tissues

Activity of a chemically modified miR-21 inhibitor in human bladder cancer xenografts. Activity of a chemically modified miR-21 inhibitor in human bladder.

Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors. Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors.

Effect of NO and eNOS on prostate cancer cell growth.

Impact of eNOS expression and treatment with GSNO on prostate tumor growth. Impact of eNOS expression and treatment with GSNO on prostate tumor growth.

MAPK/ERK signaling regulates TLR4 gene expression in response to BRAFV600E. MAPK/ERK signaling regulates TLR4 gene expression in response to BRAFV600E.

Enhanced expression of Cap43 gene by nickel in breast cancer cell lines. Enhanced expression of Cap43 gene by nickel in breast cancer cell lines. Expression.

Γ-TmT reduces serum E2 levels and induces estrogen-metabolizing enzyme CYP1A1 in E2-treated ACI rats. γ-TmT reduces serum E2 levels and induces estrogen-metabolizing.

AS1411 alters subcellular distribution of PRMT5 in a time-dependent, dose-dependent, and nucleolin-dependent manner. AS1411 alters subcellular distribution.

The effects of AZD1775 and olaparib on DNA damage response signaling.

A, DMA and Ral significantly inhibit estrone methyl ether (MeOE1) formation in MCF-10A cells. A, DMA and Ral significantly inhibit estrone methyl ether.

NEDD9 binding to AURKA decreases the efficacy of AURKA inhibitors in vitro. NEDD9 binding to AURKA decreases the efficacy of AURKA inhibitors in vitro.

Fig. 6 NicA2-J1 prevents nicotine- and stress-induced reinstatement after extinguished nicotine intake. NicA2-J1 prevents nicotine- and stress-induced.

FGFR2 amplification in primary human gastric tumors predicts for response to NVP-BGJ398. FGFR2 amplification in primary human gastric tumors predicts for.

Coculture with U937 cells enhances DNMT1 expression in gastric cancer cells. Coculture with U937 cells enhances DNMT1 expression in gastric cancer cells.

FGFR2 amplification in gastric and colon cancer cell lines is associated with response to NVP-BGJ398. FGFR2 amplification in gastric and colon cancer cell.

Presentation transcript:

Induction of liver NQO1 activity in juvenile female rats treated for 3 d (10 mg/kg qd SERMs or 0.1 mg/kg qd E2 or vehicle control). Induction of liver NQO1 activity in juvenile female rats treated for 3 d (10 mg/kg qd SERMs or 0.1 mg/kg qd E2 or vehicle control). A, distribution of individual rats in treatment groups receiving arzoxifene (Arz), DMA, F-DMA, or E2. B, cumulative data showing statistical significance of NQO1 induction by arzoxifene relative to control and significant induction by arzoxifene (P < 0.001), DMA (P < 0.005), and F-DMA (P < 0.05) relative to the E2-treated group. C, Western blot showing different levels of NQO1 expression in rat liver tissue of different groups. D, cumulative data showing the effects of 10 mg/kg qd X-DMA SERMs in antagonizing and reversing the effects of 0.1 mg/kg qd E2 on cotreatment. Data were analyzed by one-way ANOVA using Tukey's post hoc analysis. Bolan Yu et al. Mol Cancer Ther 2007;6:2418-2428 ©2007 by American Association for Cancer Research